The Big Fat Obesity Market

October 2009
Pharmaceutical Representative;Oct2009, Vol. 39 Issue 10, p21
The article focuses on the obesity market as the target of pharmaceutical companies in the U.S. It notes that obesity-related costs in the country's healthcare system has increased since 1999 and covers 9.1 percent of annual medical expenses. Drug companies reveal that additional drugs are in the Phase III trials.


Related Articles

  • Focus on Biologics Development: Oncobiologics: a case study. Jawadekar, Mak // Contract Pharma;Mar2012, Vol. 14 Issue 2, p42 

    The article presents a case study that examines the cost and duration of clinical studies in the U.S. It mentions the impact of the rising cost of drug development that has forced the pharmaceutical industry to develop business paradigm to reduce the cost of drug development. Moreover, the...

  • Drug makers' productivity hurt by steep R&D costs.  // Chain Drug Review;1/7/2013, Vol. 35 Issue 1, p69 

    The article informs that that longer development times for new treatments, the duration of clinical trials and lower success rates have elevated costs in several therapeutic categories in the U.S.

  • Five-Year Medical and Pharmacy Costs After a Medically Supervised Intensive Treatment Program for Obesity. Myers, Valerie H.; Apperson McVay, Megan; Brashear, Meghan M.; Johnson, William D.; Gupta, Alok K.; Brantley, Phillip J.; Ryan, Donna H. // American Journal of Health Promotion;Jul/Aug2014, Vol. 28 Issue 6, p364 

    Purpose. The financial impact o f intensive medical interventions for weight loss has not been fully studied. Design. A randomized pragmatic clinical trial. Setting. Seven primary care clinics and one research center in Louisiana. Subjects. Severely obese individuals (body mass index 40-60...

  • A Major Challenge for Clinical Trials.  // Chain Drug Review;2/18/2013, Vol. 35 Issue 4, p67 

    The article presents information on challenges for clinical trials of the drugs manufactured by pharmaceutical companies as recruiting and retaining patients becomes difficult in the U.S.

  • Upcoming Event Highlights.  // CenterWatch Weekly;9/21/2015, Vol. 19 Issue 37, p10 

    A calendar of events related to the U.S. pharmaceutical sector in 2015 including the 6th Annual Clinical Quality Oversight Forum in Philadelphia, Pennsylvania, the MAGI's Clinical Research Conference--2015 West and CRA & CRC Beginner Program in Boston, Massachusetts is presented.

  • National Medical Expenditures Attributable To Overweight And Obesity: How Much, And Who's Paying? Finkelstein, Eric A.; Fiebelkorn, Ian C.; Guijing Wang // Health Affairs;Jul/Aug2003, Vol. 22 Issue 4, p8 

    Doctors have spoken for years about the health dangers of obesity and being overweight, but now there is mounting evidence that these conditions are costing the United States money. This paper provides further validation of that belief, showing that health care expenditures related to treating...

  • International Research & Opinion.  // PharmacoEconomics & Outcomes News;11/27/2010, Issue 617, p12 

    The article focuses on a report, which revealed that expenditures on obesity among adults in the U.S. totaled 168 billion U.S. dollars in 2003.

  • Specialty drugs offer "reasonable value for money" in the US . . .  // PharmacoEconomics & Outcomes News;Nov2014, Vol. 714 Issue 1, p26 

    The article reports on the results of a study published in "Health Affairs" which examined the health benefits as well as the costs of specialty drugs in the U.S.

  • Prescription drug spending growth projected to escalate.  // Chain Drug Review;4/23/2012, Vol. 34 Issue 8, p66 

    The article reports that the U.S. prescription drug spending will increase as part of an overall rise in national health care expenditures and expanded health care coverage brought by the country's Patient Protection and Affordable Care Act.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics